Patents by Inventor Peter Karellas
Peter Karellas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10981858Abstract: The present invention relates to a novel dendrimer. The present invention also relates to formulations comprising the dendrimer with improved characteristics. For instance, the present invention relates to formulations comprising pesticides such as 2-(2,4-dichlorophenoxy)acetic acid with improved characteristics such as reduced crystallisation, compatibility with hard water and an extended shelf life at low temperatures.Type: GrantFiled: December 16, 2016Date of Patent: April 20, 2021Assignees: Priostar Pty Ltd, Dendritic Nanotechnologies, Inc.Inventors: Harsh Vardhan, Sarigama Rajesh, Peter Karellas
-
Publication number: 20210100910Abstract: A macromolecule includes i) a dendrimer comprising a core and at least one generation of building units, the outermost generation of building units having surface amino groups wherein at least two different terminal groups are covalently attached to the surface amino groups of the dendrimer, ii) a first terminal group which is a residue of a pharmaceutically active agent comprising a hydroxyl group, and iii) a second terminal group which is a pharmacokinetic modifying agent. The pharmaceutically active agent is cabazitaxel. The first terminal group is covalently attached to the surface amino group of the dendrimer through a diacid linker, the diacid linker comprising an alkyl chain interrupted by one or more oxygen, sulfur or nitrogen atoms, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 10, 2020Publication date: April 8, 2021Inventors: David Owen, Brian Devlin Kelly, Peter Karellas
-
Patent number: 10265409Abstract: A macromolecule includes i) a dendrimer with a core and at least one generation of lysine residue building units, the outermost generation of building units having surface amino groups, ii) a first terminal group covalently attached to a first surface amino group of a building unit, which includes a residue of docetaxel (DTX), and iii) a second terminal group covalently attached to a second surface amino group of a building unit, which includes a pharmacokinetic modifying agent. The pharmacokinetic modifying agent can be a polyethylene glycol (PEG). The first terminal group can be covalently attached to the surface amino group of the dendrimer through a diacid linker. The diacid linker can include a 2,2?-thiodiacetic acid residue. The diacid linker can form an ester bond with a hydroxyl group of the DTX and an amide bond with the surface amino group. A pharmaceutically acceptable salt of the macromolecule can be prepared.Type: GrantFiled: August 28, 2017Date of Patent: April 23, 2019Assignee: STARPHARMA PTY LTDInventors: David Owen, Brian Devlin Kelly, Peter Karellas
-
Publication number: 20180370900Abstract: The present invention relates to a novel dendrimer. The present invention also relates to formulations comprising the dendrimer with improved characteristics. For instance, the present invention relates to formulations comprising pesticides such as 2-(2,4-dichlorophenoxy)acetic acid with improved characteristics such as reduced crystallisation, compatibility with hard water and an extended shelf life at low temperatures.Type: ApplicationFiled: December 16, 2016Publication date: December 27, 2018Inventors: Harsh Vardhan, Sarigama Rajesh, Peter Karellas
-
Publication number: 20180326081Abstract: A macromolecule includes i) a dendrimer comprising a core and at least one generation of building units, the outermost generation of building units having surface amino groups wherein at least two different terminal groups are covalently attached to the surface amino groups of the dendrimer, ii) a first terminal group which is a residue of a pharmaceutically active agent comprising a hydroxyl group, and iii) a second terminal group which is a pharmacokinetic modifying agent. The pharmaceutically active agent is cabazitaxel. The first terminal group is covalently attached to the surface amino group of the dendrimer through a diacid linker, the diacid linker comprising an alkyl chain interrupted by one or more oxygen, sulfur or nitrogen atoms, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 19, 2018Publication date: November 15, 2018Inventors: David Owen, Brian Devlin Kelly, Peter Karellas
-
Publication number: 20170354739Abstract: A macromolecule includes i) a dendrimer with a core and at least one generation of lysine residue building units, the outermost generation of building units having surface amino groups, ii) a first terminal group covalently attached to a first surface amino group of a building unit, which includes a residue of docetaxel (DTX), and iii) a second terminal group covalently attached to a second surface amino group of a building unit, which includes a pharmacokinetic modifying agent. The pharmacokinetic modifying agent can be a polyethylene glycol (PEG). The first terminal group can be covalently attached to the surface amino group of the dendrimer through a diacid linker. The diacid linker can include a 2,2?-thiodiacetic acid residue. The diacid linker can form an ester bond with a hydroxyl group of the DTX and an amide bond with the surface amino group. A pharmaceutically acceptable salt of the macromolecule can be prepared.Type: ApplicationFiled: August 28, 2017Publication date: December 14, 2017Inventors: David Owen, Brian Devlin Kelly, Peter Karellas
-
Patent number: 9744246Abstract: The present invention relates to a macromolecule comprising a dendrimer having surface amino groups to which at least two different terminal groups are attached including a pharmaceutically active agent and a pharmacokinetic modifying agent, the pharmaceutically active agent comprising a hydroxyl group and being attached to the surface amino group of the dendrimer through a diacid linker. Pharmaceutical compositions comprising the macromolecules and methods of treatment using the macromolecules are also described.Type: GrantFiled: June 6, 2012Date of Patent: August 29, 2017Assignee: STARPHARMA PTY LTDInventors: David Owen, Brian Devlin Kelly, Peter Karellas
-
Publication number: 20140171375Abstract: The present invention relates to a macromolecule comprising a dendrimer having surface amino groups to which at least two different terminal groups are attached including a pharmaceutically active agent and a pharmacokinetic modifying agent, the pharmaceutically active agent comprising a hydroxyl group and being attached to the surface amino group of the dendrimer through a diacid linker. Pharmaceutical compositions comprising the macromolecules and methods of treatment using the macromolecules are also described.Type: ApplicationFiled: June 6, 2012Publication date: June 19, 2014Applicant: STARPHARMA PTY LTDInventors: David Owen, Brian Devlin Kelly, Peter Karellas
-
Patent number: 8703116Abstract: The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups.Type: GrantFiled: December 21, 2012Date of Patent: April 22, 2014Assignee: Starpharma Pty LimitedInventors: Benjamin James Boyd, Lisa Michelle Kaminskas, Christopher John Hamilton Porter, Peter Karellas, Guy Yeoman Krippner, Pasquale Razzino, Brian Devlin Kelly, Zemin Wu, Sue Pallich
-
Patent number: 8337823Abstract: The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups.Type: GrantFiled: May 15, 2006Date of Patent: December 25, 2012Assignee: Starpharma Pty LimitedInventors: Benjamin James Boyd, Lisa Michelle Kaminskas, Christopher John Hamilton Porter, Peter Karellas, Guy Yeoman Krippner, Brian Devlin Kelly, Zemin Wu, Pasquale Razzino, Sue Pallich
-
Patent number: 8158575Abstract: Use of a polylysine, polyamidoamine or polypropylenimine dendrimer having naphthyl disulphonate terminal groups as a topically applied agent in prophylaxis or treatment of sexually transmitted diseases.Type: GrantFiled: July 6, 2009Date of Patent: April 17, 2012Assignee: Starpharma Pty., LtdInventors: Barry Ross Matthews, George Holan, Peter Karellas, Scott Andrew Henderson, David Francis O'Keefe
-
Publication number: 20090324535Abstract: The present invention relates to a macromolecule having a controlled terminal group stoichiometry, the macromolecule including a surface layer, at least one subsurface layer and at least two terminal groups including: a first terminal group which is a residue of a pharmaceutically active agent, a derivative thereof or precursor therefor; and a second terminal group selected to modify the pharmacokinetics of the pharmaceutically active agent and/or macromolecule, wherein terminal group stoichiometry refers to the number and type of terminal groups.Type: ApplicationFiled: May 15, 2006Publication date: December 31, 2009Applicant: Starpharma Pty LtdInventors: Benjamin James Boyd, Lisa Michelle Kaminskas, Christopher John Hamilton Porter, Peter Karellas, Guy Yeoman Krippner, Pasquale Razzino, Brian Devlin Kelly, Zemin Wu, Sue Pallich
-
Publication number: 20090269298Abstract: Use of a polylysine, polyamidoamine or polypropylenimine dendrimer having naphthyl disulphonate terminal groups as a topically applied agent in prophylaxis or treatment of sexually transmitted diseases.Type: ApplicationFiled: July 6, 2009Publication date: October 29, 2009Inventors: Barry Ross MATTHEWS, George HOLAN, Peter KARELLAS, Scott Andrew HENDERSON, David Francis O'KEEFE
-
Patent number: 7589056Abstract: Use of a polylysine, polyamidoamine or polypropylenimine dendrimer having naphthyl disulphonate terminal groups as a topically applied agent in prophylaxis or treatment of sexually transmitted diseases.Type: GrantFiled: March 28, 2002Date of Patent: September 15, 2009Assignee: Starpharma Pty. Ltd.Inventors: Barry Ross Matthews, George Holan, Peter Karellas, Scott Andrew Henderson, David Francis O'Keefe
-
Publication number: 20050008611Abstract: Use of a polylysine, polyamidoamine or polypropylenimine dendrimer having naphthyl disulphonate terminal groups as a topically applied agent in prophylaxis or treatment of sexually transmitted diseases.Type: ApplicationFiled: March 28, 2002Publication date: January 13, 2005Inventors: Barry Matthews, George Holan, Peter Karellas, Scott Henderson, David O'Keefe